Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression

James P. Sullivan1,2, Brian V. Nahed1,3, Marissa W. Madden1, Samantha M. Oliveira1, Simeon Springer1, Deepak Bhere4, Andrew S. Chi1,4, Hiroaki Wakimoto1,3, S. Michael Rothenberg1,2, Lucia V. Sequist1,2, Ravi Kapur6, Khalid Shah4,6, A. John Iafrate1,7, William T. Curry1,3, Jay S. Loeffler1, Tracy T. Batchelor1,4, David N. Louis1,7, Mehmet Toner5,8, Shyamala Maheswaran1,8, and Daniel A. Haber1,2,9

ABSTRACT

Glioblastoma (GBM) is a highly aggressive brain cancer characterized by local invasion and angiogenic recruitment, yet metastatic dissemination is extremely rare. Here, we adapted a microfluidic device to deplete hematopoietic cells from blood specimens of patients with GBM, uncovering evidence of circulating brain tumor cells (CTC). Staining and scoring criteria for GBM CTCs were first established using orthotopic patient-derived xenografts (PDX), and then applied clinically: CTCs were identified in at least one blood specimen from 13 of 33 patients (39%; 26 of 87 samples). Single GBM CTCs isolated from both patients and mouse PDX models demonstrated enrichment for mesenchymal over neural differentiation markers compared with primary GBMs. Within primary GBMs, RNA in situ hybridization identified a subpopulation of highly migratory mesenchymal tumor cells, and in a rare patient with disseminated GBM, systemic lesions were exclusively mesenchymal. Thus, a mesenchymal subset of GBM cells invades the vasculature and may proliferate outside the brain.

SIGNIFICANCE: GBMs are locally invasive within the brain but rarely metastasize to distant organs, exemplifying the debate over “seed” versus “soil.” We demonstrate that GBMs shed CTCs with invasive mesenchymal characteristics into the circulation. Rare metastatic GBM lesions are primarily mesenchymal and show additional mutations absent in the primary tumor. Cancer Discov; 4(11): 1299-1309. ©2014 AACR.

See related commentary by Seoane and De Mattos-Arruda, p. 1259.

1Massachusetts General Hospital Cancer Center, Boston, Massachusetts. 2Department of Medicine, Harvard Medical School, Boston, Massachusetts. 3Department of Neurosurgery, Harvard Medical School, Boston, Massachusetts. 4Department of Engineering in Medicine, Harvard Medical School, Boston, Massachusetts. 5Department of Radiology, Harvard Medical School, Boston, Massachusetts. 6Department of Pathology, Harvard Medical School, Boston, Massachusetts. 7Department of Surgery, Harvard Medical School, Boston, Massachusetts. 8Howard Hughes Medical Institute, Chevy Chase, Maryland.

Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).

J.P. Sullivan and B.V. Nahed contributed equally to this article.

Corresponding Authors: Shyamala Maheswaran, Massachusetts General Hospital Cancer Center, Building 149, 13th Street, Charlestown, MA 02129. Phone: 617-726-6552; Fax: 617-726-6919; E-mail: maheswaran@helix.mgh.harvard.edu; and Daniel A. Haber, haber@helix.mgh.harvard.edu

doi: 10.1158/2159-8290.CD-14-0471
©2014 American Association for Cancer Research.
INTRODUCTION

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor, whose histologic characteristics include necrosis, infiltration into surrounding brain tissue, and microvascular proliferation. Despite advances in surgical techniques, radiotherapy, and chemotherapy, recurrence is inevitable, and 2-year survival remains at 25% (1). Major challenges to the treatment of GBM include the inability to excise tumor cells infiltrating into normal brain tissue, the poor penetration of therapeutic agents into the central nervous system (CNS), the common difficulty in distinguishing tumor responses from recurrence using standard imaging criteria, and the inherent risks associated with brain biopsies needed to monitor tumor evolution during disease progression (2).

Despite its locally aggressive features, GBMs rarely form clinically evident extracranial metastases, with only 0.4% of cases having metastases to visceral organs, including liver, spleen, kidney, and skin (3). Underdiagnosis of subclinical lesions may contribute to the infrequent documentation of systemic metastases in GBM, but the discordance between the high degree of local invasiveness and the very rare distant spread is likely to reflect inherent biologic features of the cancer. As exemplified by the “seed” versus “soil” debate (4), it is unclear whether GBM cells are incapable of invading into the vasculature, or whether invasive GBM cells circulate in the blood but are unable to proliferate in tissues outside of the brain.

Although circulating brain tumor cells (CTCs) have never been isolated in patients with GBM, they have been identified in the blood of patients with most types of epithelial cancers (reviewed in refs. 5, 6). However, their isolation presents numerous technological challenges. Even in patients with advanced cancer, CTCs typically constitute one cancer cell per billion normal blood cells (one cancer cell per million leukocytes). Most CTC detection strategies rely on antibody-mediated capture targeting cell-surface expression of the epithelial cell adhesion molecule (EpCAM), which is not present on GBM cells. We recently developed a microfluidic device, the CTC-iChip, which efficiently achieves depletion of leukocytes from blood specimens using magnetically tagged antibodies against the leukocyte markers CD45 and CD16, thereby enriching for CTCs in an antigen-agnostic manner (7). The CTC-iChip combines, within a single microfluidic platform, (i) size-based removal of red blood cells, platelets, and excess immunomagnetic beads; (ii) single file alignment of nucleated cells (leukocytes and CTCs) within a single microfluidic streamline using inertial flow dynamics; and (iii) sorting magnetically tagged leukocytes into a waste channel and isolation of untagged and unmanipulated CTCs, free in solution for application of cell-surface staining and molecular analysis. To test for the presence of GBM CTCs, we applied the CTC-iChip to an orthotopic patient-derived xenograft (PDx) GBM mouse model, and then to patients with GBM, analyzing them for characteristic molecular markers.

RESULTS

Detection of CTCs in Orthotopic GBM Mouse Xenografts

To optimize the capture and visualization of putative GBM CTCs, we first established an orthotopic xenograft model using tagged GBM cells directly inoculated into the mouse forebrain. We used two phenotypically different PDX GBM cell lines that had been directly propagated following resection under anchorage-independent sphere culture conditions, and then maintained by serial intracranial engraftment (8). GBM8 cells exhibit primitive neuroectodermal characteristics, express the stem cell marker CD133, and proliferate rapidly as loose neurosphere aggregates in vitro. Inoculation of GBM8 cells into the brain of immunosuppressed NSG mice leads to a diffusely invasive tumor that spreads along white-matter tracts, such as the corpus callosum (Fig. 1A and B and Supplementary Fig. S1A and S1B; ref. 8). In contrast, GBM24 cells lack CD133 expression, overexpress EGFR, and exhibit a classic, tight neurosphere morphology in vitro. Upon implantation into the mouse brain, they grow slowly with a nodular phenotype, including characteristic regions of intratumoral hemorrhage and tumor necrosis (Fig. 1A and B). We infected both GBM8 and GBM24 cells with mCherry-luciferase-expressing vectors, allowing in vivo imaging of tumors in the brain (luciferase expression) and definitive identification of tumor cells shed into the blood (mCherry staining; Supplementary Fig. S1A and S1B).

To generate orthotopic xenografts, 10^5 tagged GBM cells were inoculated into the frontal cortices of mice, which were then serially imaged over 5 weeks as they generated a primary tumor. To search for CTCs, a terminal intracardiac bleed was used to obtain 0.5 to 1 mL of blood, which was then directly processed through the CTC-iChip (7). Following the addition of immunomagnetic bead-conjugated anti-mouse CD45 (approximately 10^7 beads per mL), a 10^4 depletion of leukocytes was achieved, and potential CTCs admixed with residual leukocytes were subjected to imaging analysis. mCherry labeling of GBM cells made it possible to identify these in the CTC-iChip product with certainty, as well as validating neural-specific stains for application to patient-derived samples.

Given the heterogeneity of GBM and the unknown expression profile of putative GBM CTCs, we sought to develop a cocktail of antibodies that would identify a broad spectrum of GBM cells. To this end, we searched the GBM biomarker literature and used publicly available microarray data on GBM tumors (9–11), cell lines, and purified white blood cell (WBC) populations to identify GBM-specific markers (Fig. 1C). From this process, five antibodies were selected, based on their strong immunofluorescent staining of GBM8 and GBM24 cells and their complete absence in normal blood cells. This antibody cocktail, annotated as STEAM (SOX2, Tubulin beta-3, EGFR, A2B5, and c-MET), was combined into a single immunofluorescence staining channel (Supplementary Fig. S2 and Fig. 1D). GBM8 and GBM24 cells spiked directly into control blood specimens and processed through the CTC-iChip were recovered with a capture efficiency of 94.5% ± 3.7% and 93.6% ± 6.5%, respectively (mCherry staining), 85.4% ± 9.8% and 91.9% ± 3.6%, respectively (STEAM staining; Fig. 1E), and 89.7% ± 7.1% and 90.2% ± 5.9%, respectively (mCherry/STEAM staining overlap) and with minimal STEAM staining of CD45-positive leukocytes (Fig. 1F).
Mesenchymal Glioblastoma Cells in Circulation

We then applied the mCherry and STEAM stains to CTC-iChip–purified blood from mice bearing GBM8-derived (n = 11) and GBM24-derived brain tumors (n = 5). Sham-injected mice (n = 4) were used as controls. As per CTC immunofluorescence staining protocols (12), image scoring criteria were used to establish a baseline signal for mCherry staining using control tumor-free mice (median background, 3.4 cells per mL; range, 0–8.1; mean, 3.7 ± 3.6). Given this fluorescence imaging background, a positive CTC score was established as being above a threshold of 10 mCherry positive events per mL, a cutoff that is similar to that applied in previous studies of CTCs from orthotopic GBM xenograft mice (12). mCherry-positive CTCs were detected above this threshold in 5 of 11 (45.5%) and 2 of 5 (40%) mice with GBM8 and GBM24 intracranial xenografts, respectively. CTC-positive GBM8 xenograft mice had a median of 17.4 CTCs per mL (range, 11.0–27.9; mean, 18.9 ± 6.3), and the two CTC-positive GBM24 xenograft mice had 18.9 and 12.2 cells per mL (Fig. 1G and H). In all these cases, STEAM staining of CTCs yielded nearly identical cell numbers as mCherry staining, validating the multiantibody cocktail staining of circulating human GBM cells. No gross evidence of extracranial metastases was observed in CTC-positive mice by live bioluminescent imaging (BLI) or by epifluorescent imaging during necropsy. There was also no association between the size of the intracranial tumor and the number of CTCs detected (data not shown). Taken together, bona fide GBM CTCs were evident in the blood of approximately half of the mice bearing one of two phenotypically distinct intracranial xenografts of human GBM.
Having established the criteria for identifying CTCs in the mice bearing GBM xenografts, we applied this platform to peripheral blood specimens from patients with GBM, according to a Massachusetts General Hospital Institutional Review Board (IRB)–approved protocol. For leukocyte depletion of human blood samples, anti-CD66b was added to anti-CD45, given the increased fraction of low CD45-expressing leukocytes in human, compared with mouse, blood. Venous blood specimens from 33 patients with GBM and 6 healthy controls were processed through the CTC-iChip and stained simultaneously using the STEAM antibody cocktail, anti-CD14, CD16, and CD45 antibodies, and 4,6-diamidino-2-phenylindole (DAPI) nuclear stain (Fig. 2A). As with the orthotopic model, we quantified the number of fluorescent events identified in healthy controls under specific staining and imaging conditions (median background, 1.9 cells per mL; range, 0–6.4; mean, 2.6 ± 2.8) to set an imaging threshold for CTC detection (7 STEAM-positive cells per mL). STEAM-positive cells were identified above threshold in at least one blood specimen from 13 of 33 (39%) patients with GBM (26 of 87 blood samples (30%); average, 2.6 samples per patient).

The number of CTCs identified in 12 patients with progressive disease in the brain (median, 11.8 cells per mL; range, 0–32.7; n = 23 samples) was higher than that from 21 patients with stable disease (median, 2.1 cells per mL; range, 0–30.3; n = 43 samples; P < 0.001; Fig. 2B). However, univariate analysis revealed no association between detection of CTCs in at least a blood draw and other parameters, including the number of tumor foci in the brain, extent of tumor resection, or tumor genotype (Supplementary Tables S1 and S2). Whereas nearly all CTCs were detected in specimens collected from patients with GBM, nearly none were detected in specimens from healthy controls.

**Figure 2.** Identification of CTCs in the peripheral blood of patients with GBM. A, a representative immunofluorescence image of a STEAM+ CTC alongside a WBC isolated from blood of a patient with GBM. Scale bar, 20 μm. B, quantification of STEAM+ cells in healthy donor samples established a CTC detection threshold of 7 STEAM+ cells per mL. Quantification of STEAM+ cells in 64 blood samples drawn from 21 patients with stable disease and 23 blood samples from 12 patients with progressive disease (***, P < 0.001). C, left, representative images of a CTC stained with the STEAM antibody cocktail (red) and analyzed by DNA-FISH using probes against centromere 7 (CEP7, green) and EGFR (orange). Center, CEP7/EGFR DNA-FISH in matched primary tumor cells from the patient is shown. Right, table of the frequency of EGFR-amplified cells in primary tumors (n = 5) and matched STEAM+ CTCs (n = 36). Cells with focal EGFR copy gain (≥ 10 copies) are shaded in gray. Asterisk, results from a patient with metastatic GBM, presented in full later in the article. Scale bar, 20 μm. D, left, a STEAM+ CTC (red) expressing nuclear Ki67 (orange). A CD45-stained WBC is shown (green). Right, table of the frequency of Ki67+/STEAM+ CTCs (n = 28) and Ki67-positive tumor cells in the matched tumor specimens (n = 5). Scale bar, 20 μm.
at various postsurgical intervals, STEAM-positive CTCs were detected above threshold in one (11.3 STEAM-positive cells per mL) of four samples collected from preoperative GBM patients.

To verify the neoplastic origin of candidate GBM CTCs, we tested for known \textit{EGFR} genetic aberrations using FISH. CTCs captured from 6 patients whose tumors were known to have \textit{EGFR} gene amplification (\textit{EGFR}-amplified tumor cells, 73.6% ± 15.6%) were simultaneously tested for STEAM staining and \textit{EGFR} DNA-FISH. \textit{EGFR} copy gain was observed in 39 of 49 (79.6%) STEAM-positive cells (Fig. 2C). \textit{EGFR} copy gain was not observed in patient-matched WBCs, nor in CTCs matched to tumors without \textit{EGFR} amplification (Supplementary Fig. S3). Paired analysis of the frequency of CTCs with \textit{EGFR} copy gain (median, 78.9%; range, 50–100%; mean, 78.3% ± 19.9%) was similar to the frequency of patient-matched tumor cells with \textit{EGFR} copy gain (median, 72.5%; range, 55.8–97%; mean, 73.6%). Furthermore, CTCs shared the relative \textit{EGFR} copy gains observed in the bulk tumor (Fig. 2C). Although the \textit{EGFR} molecular genotype of GBM CTCs and primary GBMs was concordant, CTCs appeared to be less proliferative than the primary tumor. Indeed, comparing the proliferative index of GBM CTCs with that of the matched primary tumor showed a significantly reduced K667 score for the STEAM-positive CTCs ($P = 0.01$; Fig. 2D).

**Single-Cell Expression Analysis of GBM CTCs**

To compare the gene expression patterns of GBM CTCs with those of their parental tumors, we isolated unfixed single CTCs from the CTC-chip product by immunofluorescence-guided single-cell micromanipulation. Because the fixation and permeabilization process for STEAM staining is not compatible for the isolation of unfixed cells with intact RNA, CTCs were identified using fluorescently labeled antibodies against the surface markers identified in our candidate GBM marker screen (\textit{EGFR}, \textit{MET}, and \textit{CDH11}). Individual CTCs were interrogated by qRT-PCR (Fluidigm Corp.) for gene expression signatures, including 25 genes selected to represent four transcriptional subtypes of GBM: proneural, neural, classical, and mesenchymal (10, 14). Each subtype is defined by a transcriptional profile that has been linked with different neural lineages and disease pathophysiology (10, 14). Expression of oligodendrocyte development genes (\textit{ASCL1}, \textit{SOX2}, \textit{OLIG2}, and \textit{DLL1}) is a transcriptional hallmark of the proneural subtype, whereas classical and neural GBMs share expression of astrocytic (\textit{GFAP}, \textit{AKT2}, and \textit{EGFR}) and neuronal (\textit{SYT1} and \textit{SLC12A5}) differentiation markers, respectively. Mesenchymal GBMs exhibit a transcriptional pattern related to epithelial-mesenchymal transition (EMT) as defined for epithelial cancers, expressing astroglial differentiation and inflammatory genes (\textit{SERPINE1}, \textit{TGFBI}, and \textit{VIM}) and Notch and Hedgehog signaling components, and cell proliferation markers. \textit{GAPDH} and \textit{ACTB} expression serves as control for RNA quality, and to control for leukocyte contamination, we also measured expression of three leucocyte markers in the individually selected CTCs.

In total, we analyzed 15 single GBM CTCs from 7 independent patients, and 7 single CTCs from GBM8 and GBM24 xenografts. The primary CTCs were compared with their matched, microdissected parental tumor, whereas the xenograft-derived CTCs were compared with single tumor cells from matched xenografts as well as neurosphere cultures. Normal leukocytes contaminating the CTC product were also analyzed as controls. Unsupervised clustering analysis easily segregated CTCs from leukocytes, with leukocyte lineage markers \textit{PTPRC} and \textit{CD16} expressed in isolated WBCs and absent in GBM CTCs (Supplementary Fig. S4A).

Compared with their matched tumors, virtually all patient-derived GBM CTCs demonstrated elevated expression of the mesenchymal genes \textit{SERPINE1}, \textit{TGFBI}, \textit{TGFB2}, and \textit{VIM}, transcriptional hallmarks of the aggressive mesenchymal GBM subtype (ref. 10; Fig. 3A). They also showed consistent downregulation of neural and oligodendroglial lineage markers (\textit{ASCL1}, \textit{GFAP}, \textit{NCAM1}, and \textit{SOX9}), transcripts involved in Notch and Hedgehog signaling, as well as cell proliferation markers compared with their matched primary tumor specimens (Fig. 3A).

Like patient-derived CTCs, circulating GBM cells isolated from PDX mice were also characterized by overexpression of the mesenchymal genes \textit{SERPINE1}, \textit{TGFBI}, \textit{TGFB2}, and \textit{VIM} and by reduced expression of neural lineage and proliferative markers, compared with both primary matched tumor cells and \textit{in vitro} neurosphere cultures (Fig. 3B). Consistent with their distinct tumor of origin, GBM8 CTCs retained expression of the stem cell transcript \textit{PROM1}, which was present in single cells from the primary tumor and in neurosphere cultures. Similarly, GBM24-derived CTCs, primary tumor cells, and neurospheres shared expression of \textit{EGFR} and \textit{SOX2} (Supplementary Fig. S4B).

**Expression of Mesenchymal Genes by Subsets of Primary GBM Tumor Cells**

We used RNA \textit{in situ} hybridization (RNA-ISH) to search for subpopulations of primary GBM cells that express the high mesenchymal/low neural signature of GBM CTCs. Pooled quantifiable short nucleotide probes (ViewRNA; Affymetrix) for the four mesenchymal transcripts \textit{SERPINE1}, \textit{TGFBI}, \textit{TGFB2}, and \textit{VIM} (Fast Red) were cohybridized with pooled probes for the five neural/proneural differentiation transcripts \textit{ASCL1}, \textit{GFAP}, \textit{OLIG2}, \textit{PDGFR}, and \textit{SOX2} (Fast Blue), providing a dual-color RNA-ISH assay (17). In GBM xenografts, the human-specific RNA-ISH identified only tumor cells, without staining any normal mouse brain cells. GBM cells were classified as mesenchymal (M), neural (N), or biphenotypic (N/M). Despite the diffuse infiltrative growth pattern of GBM8, compared with the more focal phenotype of GBM24, the overall fraction of N, M, and N/M tumor cells was comparable in these two xenografts. GBM8 tumors were primarily composed of N cells (mean, 41.9% ± 6.9%) and N/M cells (52.1% ± 9.0%), with a smaller fraction of M-only cells (4.9% ± 1.9%; $n = 3$ xenografts; Fig. 4A). Comparable fractions for GBM24 were noted in N (mean, 53.8% ± 4.0%), N/M (33.7% ± 11.9%), and
Figure 3. Expression analysis of single GBM CTCs and primary tumor cells. A, top, phase contrast/immunofluorescence image a GBM CTC (red), red blood cells and a WBC (green) stained in solution after iChip-enrichment of patient blood (Scale bar, 20 μm). The GBM CTC was picked by microscopy-guided single-cell isolation. Bottom, a heatmap of gene expression patterns (normalized to GAPDH) in individual GBM CTCs (n = 15), primary tumor samples (n = 7), and WBCs (n = 3) derived from 7 patients with GBM. B, top, an iChip-enriched mCherry+ CTC obtained from mice carrying the GBM8 xenograft (red) before isolation for molecular analysis. Bottom, expression heatmap of single cells isolated from GBM8 and GBM24 neurosphere cultures (n = 8 and 7, respectively), xenografts (n = 8, each), and CTCs (n = 4 and 3, respectively). Scale bar, 20 μm. The genes analyzed by Fluidigm qPCR are shown on the left.

and M-only cells (18.6% ± 7.9%; n = 3 xenografts; Fig. 4B). In addition, the two xenografts showed striking patterns in the geographic distribution of M-only GBM cells: In the highly infiltrative GBM8 tumor, M cells were admixed throughout the tumor mass, but were more predominant at the invasive edge of the deep white-matter tracts (mean M cells, 42.5% ± 10.6%) compared with the bulk tumor population (P = 0.0015; Fig. 4A). In GBM24, M-only cells were also increased in deep white matter (mean M cells, 66.7% ± 4.7%; P = 0.016), and they also surrounded the necrotic foci (palisading cells) that are characteristic of this xenograft. M-only tumor cells were significantly increased within 100 μm of necrotic foci (mean M cells, 65.9% ± 7.3%), compared with the frequency of M-only cells in the bulk GBM24 cell population (mean M cells, 18.6% ± 7.3%; P = 0.003; Fig. 4B). Notably, palisading cells surrounding hypoxic and vaso-occlusive necrotic foci in GBM are thought to be enriched for migratory and potential tumor stem cell components (18–21).

We extended this neural/mesenchymal RNA-ISH assay to formalin-fixed, paraffin-embedded (FFPE) sections from...
patients with GBM. The proportion of tumor cells staining as M, N/M, or N was comparable with that observed in GBM xenografts (mean N cells, 34.6% ± 9.9%; N/M cells, 51.5% ± 14.9%; M cells, 14.0% ± 12.1%; n = 7). Similarly, most GBM cells expressing only mesenchymal transcripts were present in perinecrotic foci enriched in palisading cells (mean M cells, 65.0% ± 5.7%), compared with the frequency of M-only cells in the total tumor cell population (mean M cells, 14.1% ± 12.1%; P = 0.014; Fig. 4C).

**GBM CTCs in a Patient with Multiple Visceral Metastases**

Together, the characterization of CTCs from patients and xenografts suggests that, despite the absence of visceral metastases, brain tumor cells are detectable within the bloodstream, where they express a more mesenchymal and less differentiated phenotype than the matched parental tumor. Despite the rarity of patients with metastatic GBM lesions, one such case was available for molecular analysis. The patient, a 63-year-old man, underwent a subtotal resection of a left temporal lobe GBM, which was subjected to SNaPshot genotyping and tests for common gene amplification (22, 23). Only focal amplification of *EGFR* was observed. Within 14 months of the initial diagnosis, a recurrent lesion was resected in the right temporal lobe, and routine screening revealed bilateral pulmonary nodules and hilar lymphadenopathy. Repeated SNaPshot analysis of the tumor revealed only low-level *EGFR* amplification (<15 copies). The patient expired.
22 months after the initial diagnosis. Histopathologic and molecular analysis of a lymph node biopsy and of pulmon-ary nodules collected at autopsy confirmed metastatic EGFR-amplified GBM (Supplementary Fig. S5A). Analysis of peripheral blood samples obtained 12 months after diagnosis revealed a high number of CTCs (48.2 cells per mL), which were similar to the primary and metastatic tumors in their pleomorphic morphology and presence of EGFR amplification (Supplementary Fig. S5B). RNA-ISH analysis of the recurrent intracranial GBM showed an admixture of N (19.0%), N/M (65.3%), and M (15.7%) cells (Fig. 4D). In contrast, M-only cells comprised the majority of GBM cells present in the metastatic left hilar lymph node (61.6%) and in the pulmonary metastases (53.9%; Fig. 4D).

To test for genetic lesions that may contribute to the metastatic dissemination of GBM, we subjected the primary lesion, the major right pulmonary metastasis, and normal CNS tissue (as germline control) to next-genera-tion sequencing of 1,000 cancer-associated genes. Identified somatic mutations were then tested in multiple independ-ent visceral lesions, generating a schematic representation of clonal progression for metastatic GBM. Enrichment of a PDGFRB mutation from 3.5% allele frequency in the primary tumor to approximately 50% allele frequency in all five metastatic lesions was indicative of a mutant PDGFRB tumor-initiating subpopulation for extracranial metastases (Fig. 4E). Acquired mutations in EGFR, R1, and SETD2 were absent in the primary tumor but were present in all five metastatic sites (i.e., “truncal mutations”; Fig. 4E).

Additional mutations in PHP6, GSK3, JAK3, and VRK3 were restricted to more distal branches, consistent with the evolution of secondary mutations from metastatic lesions in the lower lobe of the right lung to more distal lesions in the upper lobe of the left lung and chest wall (Fig. 4E). Taken together, although no singular genetic abnormality may account for metastatic dissemination of GBM cells in this case, the relatively high number of CTCs, the high mesenchymal expression pattern of CTCs, and acquired mutations in oncogenic pathways may have contributed to this phenomenon.

**DISCUSSION**

We report that patients with glioblastoma have CTCs within the peripheral blood. Because these cells are very rare and express a subset of markers present in primary GBMs, their identification was made possible by our develop-ment of a “negative-depletion” CTC-iChip, which effec-tively removes leukocytes from blood samples, enriching for CTCs without requiring tumor cell-specific capture antibodies (7). Validation of CTCs as being derived from GBMs includes mCherry tagging of patient-derived brain tumor cells orthotopically injected into a mouse brain tumor model, staining of primary CTCs from patients with GBM using a panel of glioma markers (STEAM), and demon-tration of EGFR gene amplification in CTCs from cases known to have such amplifications in the primary tumor. Molecular characterization of expression markers within individual GBM CTCs identified enrichment for mesenchymal transcripts and reduction of neural differenti-ation markers, pointing to a subset of cells within primary GBM tumors with such profiles, which were identifiable by RNA-ISH. Together, these observations raise the possibility that a subset of primary GBM cells expressing abundant mesenchymal transcripts gain access to blood vessel lumina within the brain and circulate in the systemic vasculature. Furthermore, the identification of CTCs in patients with GBM raises the possibility that their detection and analysis may ultimately be of clinical utility in monitoring patients with this relatively inaccessible tumor.

Of the 33 patients with GBM enrolled in our study, how-ever, only 39% had detectable CTCs in at least one of an aver-age 2.6 venous blood draws. Patients with progressive disease tended to have a greater frequency of CTCs. On the basis of our limited dataset, we could not determine whether surgical or radiation-induced disruption of the blood–brain barrier (BBB) enhances CTC dissemination, but we note that 1 of 4 patients tested before either surgery or radiotherapy had a small number of CTCs in the peripheral blood, pointing to the ability of GBM cells to intravasate in the absence of ther-apy-mediated BBB disruption. With further improvements in the sensitivity of detection, CTC analyses could play a role in disease monitoring; for instance, in the clinical setting of “pseudoprogression,” where radiographic imaging frequently fails to distinguish between treatment-related responses and tumor recurrence, sometimes necessitating a repeat brain biopsy (2).

Although not of immediate clinical utility, the analysis of GBM CTCs provides biologic insights into the process of GBM invasion and the apparent paradox of rare systemic metastases in a highly invasive and angiogenic cancer. Recent expression profiling of bulk primary tumor RNA has sug-gested distinct subtypes of primary GBM, defined in part by the expression of neural/proneural (N) differentiation versus M markers (10, 14). Our RNA-ISH studies provide further resolution at the level of single cells and point to geographically distinct M tumor cell subpopulations within all GBMs analyzed. M-GBM cells are predominant within white-matter tracts in the brain, which are sites classically associated with the invasion of GBM cells and which thus serve as a conduit for the dissemination of GBM cells to different parts of the brain. In contrast with the evident M-GBM cells, few N-GBM cells are evident within these white-matter tracts. In addition, M-GBM cells are enriched among the GBM cells that constitute the characteristic palisades surrounding necrotic foci in the primary tumor. These histologic structures are thought to harbor stem-like tumor cells, which serve as a reservoir of GBM self-renewal and during disease progression (19–21). The coincidence of mesenchymal transcript expression within this cancer stem cell niche suggests a role for a process similar to EMT in GBM homeostasis and systemic circulation. Such a cell fate transition presumably reflects the aberrant activation of a developmental program by which neuroepithelial precursors migrate to form neural crest derivatives (24). Character-istic regulators of mesenchymal cell fate, including TWIST1, SNAI2, and elements of the TGFβ and NF-κB signaling pathways, are overexpressed in the mesenchymal subset of GBM (10, 14, 25, 26), which is associated with...
resistance to standard therapies and a poor prognosis (15). Individual GBMs have been reported to switch among the major subtypes in response to therapy and during progression (14, 16). Our RNA-ISH studies of primary GBMs are consistent with these findings, suggesting that subpopulations coexist within a single tumor and that such apparent cell-fate switching may result in part from the effect of selective pressures on heterogeneous cancer cell populations (27).

All of the GBM CTCs detected in patient samples as well as patient-derived xenografts shared a mesenchymal expression profile. Similarly, in the index GBM patient with multiple systemic metastases, all of these extracranial lesions were predominantly mesenchymal. Although limited in the number of events observed, these findings are consistent with M-GBM cells being more invasive into the bloodstream and, on rare occasion, competent to produce metastases outside of the brain. Brain tumors present the ultimate paradox in the classic “seed versus soil” debate on the relative roles of intrinsic tumor cell biology versus host microenvironment in the distant spread of cancer (4). GBM cells display genetic lesions that are similar to those of epithelial cancers, invade diffusely within the brain, and mediate a profound angiogenic reaction within the primary tumor, with areas of necrosis and hemorrhage (2, 10, 14). Indeed, our detailed genetic analysis of the index patient demonstrated EGFR copy gain in the primary tumor and acquisition of both dominant “truncal” mutations and secondary “branch” mutations as metastatic lesions progressed from one site to multiple sites. The nature of these mutations, as well as their oligoclonal progression, is analogous to those reported for epithelial cancers such as breast and kidney (28, 29). These acquired mutations present in metastatic lesions are likely to confer additional invasive properties, consistent with those proposed in epithelial cancers that metastasize more frequently.

Despite the detection of GBM CTCs, the absence of systemic metastases in the majority of patients with GBM is unexplained. Although the number of CTCs detectable in the blood of patients with GBM is low, it is within the broad range observed using microfluidic platforms with other types of cancers, all of which give rise to systemic metastases (7, 12). As such, it suggests that GBM cells are able to enter the systemic vascular system and survive there long enough for detection, but that they are only rarely capable of initiating gross metastatic lesions in visceral organs. It is possible that GBM cells require critical neural-specific growth factors that are absent outside the brain. We were unable to identify autocrine activation of such pathways within the visceral metastatic lesions of the index patient, using growth factor receptor arrays (data not shown). Alternatively, immune-mediated suppression of GBM cells harboring epitopes that are usually masked by the BBB, and hence considered foreign, may underlie the general failure of GBM proliferation in visceral organs. Both of these models warrant further investigation. Together, the identification of GBM CTCs and their detailed characterization may provide insight into the invasive properties of these aggressive brain tumors, ultimately identifying new therapeutic opportunities to suppress proliferation of primary GBMs.

METHODS

See Supplementary Materials for a full description of methods.

Primary GBM Culture

Early passage GBM8 and GBM24 cells were derived from patient specimens, modified by lentiviral infection to stably express luciferase and mCherry, and were maintained in vitro and in neurosphere culture conditions as previously described (8, 30). Cultures were verified periodically by DNA-FISH for known copy aberrations and routinely tested, and all were negative for mycoplasma infection (8).

CTC Isolation from Clinical Specimens

Consenting patients with World Health Organization (WHO) grade 4 glioblastoma receiving treatment at the Massachusetts General Hospital (Boston, MA) were accrued for this study according to an IRB-approved protocol. Whole blood (10–20 mL) was collected on one or more occasions from a total of 34 patients and from 5 healthy volunteers, under a separate IRB-approved protocol, for CTC analysis as previously described (7). Cells enriched with the CTC-Chip were collected in buffered solution and immediately spun onto glass slides (Shandon EZ Megafunnel; Thermo Scientific) for STEAM immunofluorescence (7) or processed for fluorescence-guided single-cell micromanipulation (see Supplementary Methods for a full description).

RNA Expression Analyses of Single Cells and FFPE Tissue Specimens

RNA extracted from FFPE tissues (AllPrep DNA/RNA FFPE kit; Qiagen) and from lysed single cells were reverse transcribed and processed for Fluidigm Single Cell Gene Expression analysis as described previously (7, 31). A brief preamplification of target transcripts was performed using a custom panel of 49 validated gene primer pairs (DELTAgene Assay; Fluidigm Corp.), followed by qPCR analysis on a BioMark HD Real-Time PCR System (Fluidigm Corp.). Dual-color RNA-ISH of FFPE tissues was performed using custom-designed QuantiGene ViewRNA probes (Affymetrix) against neural (ASCL1, GFAP, Olig2, PDGFRα, and SOX2) and mesenchymal GBM subtype transcripts (SERPINE1, TGFB1, TGFB2, and VIM; see Supplementary Methods for a full description of these assays).

Disclosure of Potential Conflicts of Interest

L.V. Sequist is a consultant/advisory board member for Clovis Oncology, Boehringer Ingelheim, Merrimack Pharmaceuticals, AstraZeneca, Genentech, Novartis, and Taiho. T.T. Batchelor reports receiving commercial research grants from AstraZeneca, Pfizer, and Millennium Pharmaceuticals; has received honoraria from the speakers’ bureaus of Research To Practice, Up to Date, Inc., Imexed, Oakstone Medical Publishing, Educational Concepts Group, Robert Michael Educational Institute, American Academy of Neurology, and American Society of Hematology; and is a consultant/advisory board member for Agenus, Novartis, Roche, Merck, Proximagen, Kirin, Advance Medical, and Champions Biotechnology. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.P. Sullivan, B.V. Nahed


Writing, review, and/or revision of the manuscript: J.P. Sullivan, B.V. Nahed, A.S. Chi, H. Wakimoto, A.J. Iafrate, W.T. Curry, J.S. Loeffler, T.T. Batchelor, D.N. Louis, M. Toner, S. Maheswaran, D.A. Haber

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B.V. Nahed, S.M. Oliveira, D. Bhere, H. Wakimoto, J.S. Loeffler, M. Toner, S. Maheswaran, D.A. Haber

Study supervision: B.V. Nahed, L.V. Sequist, W.T. Curry, S. Maheswaran, D.A. Haber

Other (development of underlying technology for tumor cell isolation): R. Kapur

Acknowledgments

The authors thank Drs. R. Martuza, M. Frosch, S. Stott, G. Mohapatra, J. Dietrich, J. Walsh, P. Sphuler, and A. Shah for reagents and technical support; C. Koris and J. Brown for coordinating patient sample procurement; and the patients and their families for their participation in this study.

Grant Support

This work was funded by grants from the NIH K12CA090354, P50CA165962, and NIHLRP (to T.T. Batchelor, D.A. Haber, and B.V. Nahed); B* Cure (to B.N. Nahed); Voices Against Brain Cancer (to D.A. Haber); and the St. Jude Children’s Research Hospital (to D.A. Haber).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 7, 2014; revised August 6, 2014; accepted August 15, 2014; published OnlineFirst August 19, 2014.

REFERENCES

Mesenchymal Glioblastoma Cells in Circulation

### Research Brief


